Form 4 for MREO Mereo BioPharma Group plc
Accepted 2024-06-25 00:00:00 ET · period of report 2024-06-21 · accession 0000950170-24-077487 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-25 | 2024-06-21 | MREO | Lewicki John A. | CSO | M - OptEx | $0.00 | +69.0K | 73.0K | +1,724% | $0 |
| D | 2024-06-25 | 2024-06-21 | MREO | Lewicki John A. | CSO | M - OptEx | $0.00 | +69.0K | 46.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American Depositary Shares representing Ordinary Shares | 2024-06-21 | M | A | 69,000 | $0.00 | 73,003 | D | — | — | (F1) Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. (F2) Represents performance-based restricted stock unit ("PSU") earned under the issuer's 2019 Employee Incentive Plan (the "Plan") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025). |
| 2 | Derivative | Performance Based Restricted Stock Unit | 2024-06-21 | M | A | 69,000 | $0.00 | 46,000 | D | $0.00 · 2024-06-21 to 2025-01-25 | 69,000 American Depository Shares |